EverythingALS has launched a new online tool called SAVA AI that uses artificial intelligence to instantly match people with amyotrophic lateral sclerosis (ALS) to clinical trials.

Masitinib treatment for ALS led to 42% of patients in a clinical trial surviving five years, nearly double historical rates, ...

The news last week that a Phase 3 trial of Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis drug — marketed as Relyvrio — failed to benefit patients compared to placebo hit the ALS patient ...

WASHINGTON (AP) — The Food and Drug Administration meets this week to consider approval of an experimental treatment for Lou Gehrig’s disease, the culmination of a yearslong lobbying effort by ...

The core facilities of the Cibio Department of the University of Trento have all taken part in a study on amyotrophic lateral ...

SAVANNAH, GEORGIA — Remote monitoring of respiratory scores in patients with amyotrophic lateral sclerosis (ALS) helps predict the best timing for the introduction of bilevel positive airway pressure ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Researchers have found that patients with amyotrophic lateral sclerosis have ...

Michael Podolsky, a 44-year-old man diagnosed with amyotrophic lateral sclerosis (ALS), died on September 25 at Sheba Medical Center in Tel HaShomer after a Tel Aviv District Court granted his request ...

Unlike other pathologies, amyotrophic lateral sclerosis (ALS) cannot be reproduced accurately in animal models, complicating the development of effective drugs. Faced with this challenge, a group of ...

More than four months after a Chicago woman battling ALS was told she couldn't get a disabled parking placard in front of her ...